Trial Profile
A phase I study of subcutaneous alemtuzumab in combination with oral fludarabine in previously untreated patients with chronic lymphocytic leukaemia.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2019
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Fludarabine (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms FULLSCALE
- 03 Mar 2019 Status changed from recruiting to discontinued.
- 26 May 2011 New trial record